Science Corporation raises oversubscribed $230M Series C to commercialize PRIMA retinal BCI in Europe first
Summary
Science Corporation closed an oversubscribed $230 million Series C in March 2026, with the expected upcoming commercial launch of PRIMA in Europe making them poised to be the first BCI company with a vision restoration product on the market. Beyond PRIMA, the round also funds expansion of Science's Biohybrid neural interface technology, Vessel perfusion platform, MEMS Foundry capabilities, and BCI Ecosystem business. Science also appointed Darius Shahida as Chief Strategy Officer in January 2026 to lead commercialization strategy. The company is simultaneously advancing US FDA Breakthrough Device application while pursuing CE mark.
Why it matters
Science Corporation becoming the first BCI company with a commercial vision restoration product would be a landmark in the history of neural engineering. Neuralink has more media attention, but Science may reach the market first. PRIMA's NEJM publication and Time cover generate the consumer awareness that transforms a clinical approval into commercial demand — patients know what PRIMA is before their ophthalmologist mentions it.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial